Menu Search
Equities

Enovis Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
C520:DUS

Enovis Corp

Actions
  • Price (EUR)18.80
  • Today's Change0.10 / 0.53%
  • Shares traded25.00
  • 1 Year change-56.68%
  • Beta1.2496
Data delayed at least 15 minutes, as of Feb 06 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).

  • Revenue in USD (TTM)2.23bn
  • Net income in USD-1.37bn
  • Incorporated1998
  • Employees7.37k
  • Location
    Enovis Corp2711 CENTERVILLE ROAD, SUITE 400WILMINGTON 19808United StatesUSA
  • Phone+1 (302) 252-9160
  • Fax+1 (301) 323-9001
  • Websitehttps://www.enovis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.